The Norwegian Tenecteplase Stroke Trial 2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 201 participants.
Also called NCT03854500
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 201 participants
- Registry
-
NCT03854500
-
- Main results
- Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Norway
- Registry status
- Terminated
Technical summary
Registry record NCT03854500. Randomized; double masking; primary purpose treatment. Start 2019-10-28 (actual); primary completion 2021-09-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Norwegian Tenecteplase Stroke Trial 2
- Acronym
- NOR-TEST 2
- Condition
- Stroke, Acute
- Condition
- Cerebrovascular Disorders
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Tenecteplase
- Intervention (Drug)
- Alteplase
- Lead sponsor
- Haukeland University Hospital
Record details
- Record id
cardio:ct-nct03854500- Content hash
6d40df9bb6592a57277eaff80aee0690ebe2edfe437fd9a4d43de37df8d75d4b